Advances in incretin-based therapeutics for obesity

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Advances in incretin-based therapeutics for obesity. / Rosenkilde, Mette M.

I: Nature Reviews Endocrinology, Bind 20, 2024, s. 67–68.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Rosenkilde, MM 2024, 'Advances in incretin-based therapeutics for obesity', Nature Reviews Endocrinology, bind 20, s. 67–68. https://doi.org/10.1038/s41574-023-00938-w

APA

Rosenkilde, M. M. (2024). Advances in incretin-based therapeutics for obesity. Nature Reviews Endocrinology, 20, 67–68. https://doi.org/10.1038/s41574-023-00938-w

Vancouver

Rosenkilde MM. Advances in incretin-based therapeutics for obesity. Nature Reviews Endocrinology. 2024;20:67–68. https://doi.org/10.1038/s41574-023-00938-w

Author

Rosenkilde, Mette M. / Advances in incretin-based therapeutics for obesity. I: Nature Reviews Endocrinology. 2024 ; Bind 20. s. 67–68.

Bibtex

@article{d774fd634ad24957b6bf8ea67ac48070,
title = "Advances in incretin-based therapeutics for obesity",
abstract = "The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.",
author = "Rosenkilde, {Mette M.}",
year = "2024",
doi = "10.1038/s41574-023-00938-w",
language = "English",
volume = "20",
pages = "67–68",
journal = "Nature reviews. Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Advances in incretin-based therapeutics for obesity

AU - Rosenkilde, Mette M.

PY - 2024

Y1 - 2024

N2 - The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.

AB - The year 2023 brought reports of highly effective glucagon-like peptide 1 (GLP1) mono-agonists or combinations with amylin receptor agonists. Results for monomolecular co-agonists that added glucagon receptor and/or glucose-dependent insulinotropic polypeptide (GIP) receptor agonism to GLP1 receptor activation were also published in 2023. Interestingly, antagonistic GIP receptor antibodies conjugated with a GLP1 agonist were also shown to be effective.

U2 - 10.1038/s41574-023-00938-w

DO - 10.1038/s41574-023-00938-w

M3 - Journal article

C2 - 38062121

AN - SCOPUS:85179364905

VL - 20

SP - 67

EP - 68

JO - Nature reviews. Endocrinology

JF - Nature reviews. Endocrinology

SN - 1759-5029

ER -

ID: 377451023